Frequency of ALK and GD2 Expression in Neuroblastoma

Aygün, Zeynep; Batur, Şebnem; Emre, Şenol; Çelkan, Tiraje; Özman, Oktay; Çomunoğlu, Nil

doi:10.1080/15513815.2019.1588439

Cited by 9 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median value of CD34 (+) cell count in the stem cell product given in the first transplantation was 7.5 (range, 4.55-17.1) ×10⁶ cells/kg. The median day of myeloid and platelet engraftment was detected as +12 (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) days and +18 (12-28) days, respectively. The mean time between two HSCT was 4.7±0.5 months.…”

Section: Resultsmentioning

confidence: 99%

“…Standard care of high-risk NBL is defined as multi-modal treatment which includes induction chemotherapy, surgical tumor resection, immunotherapy, consolidative highdose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT), post-consolidation therapy to treat minimal residual disease including isotretinoin, post-transplant radiotherapy (8,9,10). Detection of GD2 and ALK expression in neuroblastoma cells brings up alternative treatment options (11). Survival is around less than %15 before these intense therapies but, it is still below 50% despite all these treatment regimens (9,10).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transplantation for ultra high-risk neuroblastoma patients: effect of tandem autologous stem cell transplantation

Yılmaz¹,

Samur²,

Özcan³

et al. 2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

Aim: Neuroblastoma is a tumor with a high mortality rate originating from primitive sympathetic ganglion cells. In recent years, the definition of "ultra high-risk" has been used, in which the response to treatment is added in addition to the disease characteristics. In this study, the results of tandem high-dose Iodine 131 (131I) metaiodobenzylguanidine (MIBG) and tandem autologous hematopoietic stem cell transplantation (HSCT) in patients who were diagnosed as refractory after first-line treatments and considered with ultra-high risk nöroblastom (NBL) in Erciyes University Medical Faculty Pediatric Bone Marrow Transplant Center were shared. Material and Method: Eleven patients who underwent tandem MIBG and autologous HSCT with the diagnosis of refractory/ultra high-risk NBL between 2011 and 2021 were included in the study. Patient's data were obtained retrospectively using an electronic or manuscript medical record. Results: Tandem autologous HSCT and MIBG treatment were applied to 11 patients with a median age of 40.5 months who were diagnosed with refractory/ultra high-risk neuroblastoma. In our study, the overall survival rate was 54.5% and event-free survival (EFS) was 39% at a median follow-up of 20.7 (7.8-105.6) months. Of the 6 surviving patients, 4 are followed in complete remission and 2 in partial remission. Conclusion: Our study is the only study that includes a group of patients who received tandem high-dose MIBG and tandem autologous HSCT transplantation in refractory NBL patients without cytokine and immunotherapy. Tandem transplantation and MIBG therapy in ultra-high-risk NBL cases remain promising with acceptable toxicity. Adding immunotherapy to this treatment protocol and combining it with new treatment modalities such as anaplastic lymphoma kinase (ALK), which also takes into account genetic characteristics, may increase survival and event-free survival rates.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Transplantation for ultra high-risk neuroblastoma patients: effect of tandem autologous stem cell transplantation

Yılmaz¹,

Samur²,

Özcan³

et al. 2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

show abstract

“…Remarkable advancement has been achieved in the ever-greater understanding of the genetic etiology of neuroblastoma. 10 , 11 , 12 Mutations in the PHOX2B 13 and ALK 14 , 15 genes frequently predispose children to familial neuroblastoma. The introduction of single-nucleotide polymorphism (SNP) array technology in the 1990s 16 enabled genome-wide association studies (GWASs) in the late 2000s.…”

Section: Introductionmentioning

confidence: 99%

METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study

Zhang

Zhu

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Neuroblastoma is the primary cause of cancer death in childhood. METTL14 is tightly linked to cancer. However, whether single-nucleotide polymorphisms (SNPs) in the METTL14 gene could predispose to neuroblastoma susceptibility lacks evidence. With an epidemiology case-control study, associations between METTL14 gene SNPs and overall risk for neuroblastoma were estimated in 898 cases and 1,734 controls. Following that, stratified analysis was performed. Among the five analyzed SNPs, rs298982 G>A and rs62328061 A>G exhibited a significant association with decreased susceptibility to neuroblastoma, whereas the associations with increased neuroblastoma susceptibility were observed for rs9884978 G>A and rs4834698 T>C. Moreover, subjects carrying two to five risk genotypes were more inclined to develop neuroblastoma than those with zero to one risk genotypes. The stratified analysis further demonstrated the protective effect of rs298982 G>A and rs62328061 A>G, as well as the predisposing effect of rs4834698 T>C and two to five risk genotypes, in certain subgroups. Haplotype analysis was performed. Moreover, false-positive report probability analysis validated the reliability of the significant results. The expression quantitative trait locus analysis revealed that rs298982 is correlated with the expression levels of its surrounding genes. Our results suggest that some SNPs in the METTL14 gene are associated with predisposition to neuroblastoma.

show abstract

“…13,14 Previous research has suggested that there is a strong genetic component underlying neuroblastoma susceptibility. 15 For example, most of the familial neuroblastoma harboured mutations in genes ALK 16,17 and PHOX2B. 18 A clinical trial of an inhibitor of ALK was launched soon after the initial discovery of ALK mutations.…”

Section: Introductionmentioning

confidence: 99%

Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine‐centre case‐control study

Bian

Zhang

Zhu

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Neuroblastoma ranks as the most commonly seen and deadly solid tumour in infancy. The aberrant activity of m 6 A‐RNA methyltransferase METTL3 is involved in human cancers. Therefore, functional genetic variants in the METTL3 gene may contribute to neuroblastoma risk. In the current nine‐centre case‐control study, we aimed to analyse the association between the METTL3 gene single nucleotide polymorphisms (SNPs) and neuroblastoma susceptibility. We genotyped four METTL3 gene SNPs (rs1061026 T>G, rs1061027 C>A, rs1139130 A>G, and rs1263801 G>C) in 968 neuroblastoma patients and 1814 controls in China. We found significant associations between these SNPs and neuroblastoma risk in neither single‐locus nor combined analyses. Interestingly, in the stratified analysis, we observed a significant risk association with rs1061027 AA in subgroups of children ≤ 18 months of age (adjusted OR = 1.87, 95% CI = 1.03‐3.41, P = .040) and females (adjusted OR = 1.86, 95% CI = 1.07‐3.24, P = .028). Overall, we identified a significant association between METTL3 gene rs1061027 C>A polymorphism and neuroblastoma risk in children ≤18 months of age and females. Our findings provide novel insights into the genetic determinants of neuroblastoma.

show abstract

Frequency of ALK and GD2 Expression in Neuroblastoma

Cited by 9 publications

References 22 publications

Transplantation for ultra high-risk neuroblastoma patients: effect of tandem autologous stem cell transplantation

Transplantation for ultra high-risk neuroblastoma patients: effect of tandem autologous stem cell transplantation

METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study

Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine‐centre case‐control study

Contact Info

Product

Resources

About